Qyuns Therapeutics is one of the leading companies in the field of autoimmune and allergic diseases in China. [Photo/WeChat account: weigg6666]
Qyuns Therapeutics in the Taizhou Medical High-tech Zone, Jiangsu province, recently announced an exclusive global cooperation and licensing deal with F. Hoffmann La Roche Ltd (Roche) for its self-developed long-acting dual antibody, QX031N injection.
QX031N is expected to be developed as a new treatment option for respiratory diseases such as chronic obstructive pulmonary disease (COPD) and asthma.
According to the agreement, Roche will be granted exclusive global rights to research, develop, register, produce, and commercialize QX031N.
In return, Qyuns will receive a one-time upfront payment of $75 million and be eligible for up to $995 million in milestone payments related to product development, regulatory approvals, and commercialization, as well as tiered royalty fees for potential future product sales.
Founded in 2015, Qyuns is a high-tech biopharmaceutical enterprise specializing in biological therapies for autoimmune and allergic diseases.